172 related articles for article (PubMed ID: 21317558)
1. Ranolazine block of human Na v 1.4 sodium channels and paramyotonia congenita mutants.
El-Bizri N; Kahlig KM; Shyrock JC; George AL; Belardinelli L; Rajamani S
Channels (Austin); 2011; 5(2):161-72. PubMed ID: 21317558
[TBL] [Abstract][Full Text] [Related]
2. State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine.
Wang GK; Calderon J; Wang SY
Mol Pharmacol; 2008 Mar; 73(3):940-8. PubMed ID: 18079277
[TBL] [Abstract][Full Text] [Related]
3. Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine.
Rajamani S; Shryock JC; Belardinelli L
Channels (Austin); 2008; 2(6):449-60. PubMed ID: 19077543
[TBL] [Abstract][Full Text] [Related]
4. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block.
Desaphy JF; De Luca A; Didonna MP; George AL; Camerino Conte D
J Physiol; 2004 Jan; 554(Pt 2):321-34. PubMed ID: 14608015
[TBL] [Abstract][Full Text] [Related]
5. Block of Na+ currents and suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine.
Hirakawa R; El-Bizri N; Shryock JC; Belardinelli L; Rajamani S
Neuropharmacology; 2012 Jun; 62(7):2251-60. PubMed ID: 22313527
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization and cold sensitivity of T1313A, a new mutation of the skeletal muscle sodium channel causing paramyotonia congenita in humans.
Bouhours M; Sternberg D; Davoine CS; Ferrer X; Willer JC; Fontaine B; Tabti N
J Physiol; 2004 Feb; 554(Pt 3):635-47. PubMed ID: 14617673
[TBL] [Abstract][Full Text] [Related]
7. Use-dependent block of cardiac late Na(+) current by ranolazine.
Rajamani S; El-Bizri N; Shryock JC; Makielski JC; Belardinelli L
Heart Rhythm; 2009 Nov; 6(11):1625-31. PubMed ID: 19879541
[TBL] [Abstract][Full Text] [Related]
8. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action.
Beyder A; Strege PR; Reyes S; Bernard CE; Terzic A; Makielski J; Ackerman MJ; Farrugia G
Circulation; 2012 Jun; 125(22):2698-706. PubMed ID: 22565935
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
Fredj S; Sampson KJ; Liu H; Kass RS
Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine selectively blocks persistent current evoked by epilepsy-associated Naν1.1 mutations.
Kahlig KM; Lepist I; Leung K; Rajamani S; George AL
Br J Pharmacol; 2010 Nov; 161(6):1414-26. PubMed ID: 20735403
[TBL] [Abstract][Full Text] [Related]
11. N1366S mutation of human skeletal muscle sodium channel causes paramyotonia congenita.
Ke Q; Ye J; Tang S; Wang J; Luo B; Ji F; Zhang X; Yu Y; Cheng X; Li Y
J Physiol; 2017 Nov; 595(22):6837-6850. PubMed ID: 28940424
[TBL] [Abstract][Full Text] [Related]
12. Two human paramyotonia congenita mutations have opposite effects on lidocaine block of Na+ channels expressed in a mammalian cell line.
Fan Z; George AL; Kyle JW; Makielski JC
J Physiol; 1996 Oct; 496 ( Pt 1)(Pt 1):275-86. PubMed ID: 8910215
[TBL] [Abstract][Full Text] [Related]
13. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative.
Desaphy JF; De Luca A; Tortorella P; De Vito D; George AL; Conte Camerino D
Neurology; 2001 Nov; 57(10):1849-57. PubMed ID: 11723275
[TBL] [Abstract][Full Text] [Related]
14. Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels.
Wang GK; Russell C; Wang SY
J Physiol; 2004 Feb; 554(Pt 3):621-33. PubMed ID: 14608007
[TBL] [Abstract][Full Text] [Related]
15. A1152D mutation of the Na+ channel causes paramyotonia congenita and emphasizes the role of DIII/S4-S5 linker in fast inactivation.
Bouhours M; Luce S; Sternberg D; Willer JC; Fontaine B; Tabti N
J Physiol; 2005 Jun; 565(Pt 2):415-27. PubMed ID: 15790667
[TBL] [Abstract][Full Text] [Related]
16. Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels.
Huang H; Priori SG; Napolitano C; O'Leary ME; Chahine M
Am J Physiol Heart Circ Physiol; 2011 Jan; 300(1):H288-99. PubMed ID: 21076026
[TBL] [Abstract][Full Text] [Related]
17. Ranolazine reduces neuronal excitability by interacting with inactivated states of brain sodium channels.
Kahlig KM; Hirakawa R; Liu L; George AL; Belardinelli L; Rajamani S
Mol Pharmacol; 2014 Jan; 85(1):162-74. PubMed ID: 24202911
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of cold sensitivity of paramyotonia congenita mutation R1448H and overlap syndrome mutation M1360V.
Mohammadi B; Mitrovic N; Lehmann-Horn F; Dengler R; Bufler J
J Physiol; 2003 Mar; 547(Pt 3):691-8. PubMed ID: 12562902
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block.
Zygmunt AC; Nesterenko VV; Rajamani S; Hu D; Barajas-Martinez H; Belardinelli L; Antzelevitch C
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1606-14. PubMed ID: 21821778
[TBL] [Abstract][Full Text] [Related]
20. Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons.
Peters CH; Sokolov S; Rajamani S; Ruben PC
Br J Pharmacol; 2013 Jun; 169(3):704-16. PubMed ID: 23472826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
